Program
mirvetuximab soravtansine
Also written as “Mirvetuximab Soravtansine”, “Mirvetuximab soravtansine” and “TAK-853”.
Its studies are mostly in Carcinoma, Ovarian Epithelial · Ovarian Neoplasms · Fallopian Tube Neoplasms · Neoplasms, led by 5 companies.
Drug pageMirvetuximab soravtansine: every studyMany companies study it; this page follows only the 15 they lead. All 28 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AbbVie | 115 open or running | phase 3since Dec 10, 2015 | May 30, 2012 | Nov 2026phase 2 · NCT05456685 |
| AGO Researchits history only | 11 open or running | phase 2since Feb 10, 2020 | Feb 10, 2020 | none ahead |
| Huadong Medicineits history only | 10 open or running | phase 3since Nov 14, 2022 | Nov 14, 2022 | none ahead |
| Pheast Therapeuticsits history only | 11 open or running | phase 1since Feb 10, 2025 | Feb 10, 2025 | Apr 2029phase 1 · NCT06840886 |
| Takedaits history only | 11 open or running | phase 2since Apr 26, 2024 | Apr 26, 2024 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AbbVie only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- May 30, 2012First study: phase 1 study in NeoplasmsFirst studyNCT01609556 · 206 enrolled · United States, Canada
- Jun 9, 2015Named mirvetuximab soravtansineINNProposed as its International Nonproprietary Name in WHO's List 113 · before, TAK-853
- Nov 6, 2015Phase 2 study in Carcinoma, Ovarian EpithelialNCT02606305 · 264 enrolled · United States, Belgium, Canada and more
- Dec 10, 2015Phase 3 study in Carcinoma, Ovarian EpithelialNCT02631876 · 366 enrolled · United States, Belgium, Bosnia and Herzegovina and more
- Dec 17, 2019Phase 3 study in Carcinoma, Ovarian EpithelialNCT04209855 · 453 enrolled · United States, Australia, Belgium and more
- Feb 27, 2020Phase 3 study in Carcinoma, Ovarian EpithelialNCT04296890 · 106 enrolled · United States, Australia, Belgium and more
- Aug 24, 2021Phase 2 study in Ovarian NeoplasmsNCT05041257 · 79 enrolled · United States, Australia, Belgium and more
- Jun 29, 2022Phase 2 study in Fallopian Tube NeoplasmsNCT05456685 · 125 enrolled · United States, Belgium, Canada and more
- Jun 30, 2022Phase 3 study in Ovarian NeoplasmsNCT05445778 · 520 enrolled · United States, Argentina, Australia and more
- Nov 8, 2024Phase 2 study in Fallopian Tube NeoplasmsNCT06682988 · 110 planned · United States, Australia, Belgium and more
- Mar 20, 2025Phase 2 study in Carcinoma, Ovarian EpithelialNCT06890338 · 140 planned · United States
- Jul 2, 2025Phase 2 study in Ovarian NeoplasmsNCT07059845 · 400 planned · United States, Australia, Belgium and more
Ahead
- Nov 2026Primary completion: phase 2 study in Fallopian Tube NeoplasmsNCT05456685
- Apr 2027Primary completion: phase 3 study in Ovarian NeoplasmsNCT05445778
- Jan 2029Primary completion: phase 2 study in Ovarian NeoplasmsNCT07059845
- Feb 2030Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT06890338
TargetBeta
“An immunoconjugate consisting of the humanized monoclonal antibody M9346A against folate receptor 1 (FOLR1) ”NCIt, by rule
“Folate receptor alpha binding agent”ChEMBL 37, by rule
Other programs on FOLR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| rinatabart sesutecanrule | Genmab | phase 3 | 9 |
| torvutatug samrotecan | AstraZeneca | phase 3 | 5 |
| sofetabart mipitecan | Eli Lilly | phase 3 | 2 |
| opugotamig olatansine | AbbVie | phase 2 | 2 |
| Anti-Folate Receptor Alpha Antibody-drug Conjugate ABBV-901 | AbbVie | phase 1 | 1 |
| Anti-FRa/Anti-CD3 Bispecific TCE NTB-928rule | teneoseven-inc | phase 1 | 1 |
Studies
All 11 AbbVie leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07059845Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Jan 2029 | 400 |
| NCT06890338Carcinoma, Ovarian Epithelial · United States | 2 | Recruiting | Feb 2030 | 140 |
| NCT06682988Fallopian Tube Neoplasms · United States, Australia, Belgium and more | 2 | Recruiting | Jul 2026 | 110 |
| NCT05445778Ovarian Neoplasms · United States, Argentina, Australia and more | 3 | Active, not recruiting | Apr 2027 | 520 |
| NCT05456685Fallopian Tube Neoplasms · United States, Belgium, Canada and more | 2 | Active, not recruiting | Nov 2026 | 125 |
| NCT05041257Ovarian Neoplasms · United States, Australia, Belgium and more | 2 | Completed | Dec 12, 2024 | 79 |
| NCT04296890Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Completed | Nov 16, 2021 | 106 |
| NCT04209855Carcinoma, Ovarian Epithelial · United States, Australia, Belgium and more | 3 | Completed | Mar 6, 2023 | 453 |
| NCT02631876Carcinoma, Ovarian Epithelial · United States, Belgium, Bosnia and Herzegovina and more | 3 | Completed | Jan 2019 | 366 |
| NCT02606305Carcinoma, Ovarian Epithelial · United States, Belgium, Canada and more | 2 | Completed | Mar 12, 2021 | 264 |
| NCT01609556Neoplasms · United States, Canada | 1 | Completed | Mar 19, 2018 | 206 |
How it is read
Names in the registry
- “Mirvetuximab Soravtansine”, 8 entries
- “Mirvetuximab soravtansine”, 5 entries
- “TAK-853”, 1 entry
- “Mirvetuximab soravtansine plus Bevacizumab”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 6 studies
- Ovarian Neoplasms, 4 studies
- Fallopian Tube Neoplasms, 2 studies
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.